CA2902099C - Analyse de sang destinee a mettre en evidence des mutations de l'egfr - Google Patents

Analyse de sang destinee a mettre en evidence des mutations de l'egfr Download PDF

Info

Publication number
CA2902099C
CA2902099C CA2902099A CA2902099A CA2902099C CA 2902099 C CA2902099 C CA 2902099C CA 2902099 A CA2902099 A CA 2902099A CA 2902099 A CA2902099 A CA 2902099A CA 2902099 C CA2902099 C CA 2902099C
Authority
CA
Canada
Prior art keywords
cancer
egfr
mutation
patients
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2902099A
Other languages
English (en)
Other versions
CA2902099A1 (fr
Inventor
Barbara Klughammer
Peter Meldgaard
Boe Sorensen
Julie Tsai
Wei Wen
Lin Wu
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2902099A1 publication Critical patent/CA2902099A1/fr
Application granted granted Critical
Publication of CA2902099C publication Critical patent/CA2902099C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthodes améliorées destinées à évaluer l'état d'une tumeur solide cancéreuse chez un sujet impliquant la détection de mutations associées à la tumeur dans le sang du sujet.
CA2902099A 2013-03-08 2014-03-07 Analyse de sang destinee a mettre en evidence des mutations de l'egfr Active CA2902099C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361774946P 2013-03-08 2013-03-08
US61/774,946 2013-03-08
US201361886619P 2013-10-03 2013-10-03
US61/886,619 2013-10-03
PCT/EP2014/054409 WO2014135669A1 (fr) 2013-03-08 2014-03-07 Analyse de sang destinée à mettre en évidence des mutations de l'egfr

Publications (2)

Publication Number Publication Date
CA2902099A1 CA2902099A1 (fr) 2014-09-12
CA2902099C true CA2902099C (fr) 2020-06-02

Family

ID=50236189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902099A Active CA2902099C (fr) 2013-03-08 2014-03-07 Analyse de sang destinee a mettre en evidence des mutations de l'egfr

Country Status (7)

Country Link
US (1) US9873913B2 (fr)
EP (1) EP2964781B1 (fr)
JP (2) JP6480349B2 (fr)
CN (1) CN105229173A (fr)
CA (1) CA2902099C (fr)
ES (1) ES2662598T3 (fr)
WO (1) WO2014135669A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730930C (fr) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
CA3007787C (fr) 2010-06-03 2020-03-10 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
ES2662598T3 (es) 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
CN106133521A (zh) * 2013-10-02 2016-11-16 苏瑞科技有限公司 用于治疗异质肿瘤的病患特异性的免疫疗法
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2016029175A1 (fr) * 2014-08-21 2016-02-25 Pharmacyclics Llc Méthodes de traitement de troubles associés à des formes mutantes de l'egfr
EP3204510B1 (fr) * 2014-10-09 2018-07-25 Roche Diagnostics GmbH Nouvelles mutations complexes dans le domaine kinase du récepteur de facteur de croissance épidermique
EP3265562A4 (fr) * 2015-03-05 2018-12-19 TrovaGene, Inc. Évaluation précoce du mécanisme d'action et de l'efficacité de thérapies contre le cancer à l'aide de marqueurs moléculaires dans des fluides corporels
KR101800366B1 (ko) * 2015-07-17 2017-11-22 서울대학교산학협력단 혈장내 유리무세포 DNA(cfDNA)를 이용한 상피세포 성장인자 수용체 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
KR102449693B1 (ko) * 2016-05-25 2022-09-30 주식회사 젠큐릭스 상피세포 성장인자 수용체 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
IT201700045353A1 (it) * 2017-04-26 2018-10-26 Bioscience Services S R L Metodo per la ricerca e l'individuazione di una condizione genetica prodromica all'insorgenza di tumori solidi
JP7722675B2 (ja) * 2017-05-16 2025-08-13 公立大学法人和歌山県立医科大学 Ｅｇｆｒ変異非小細胞肺がんにおけるｅｇｆｒチロシンキナーゼ阻害剤の治療奏功性の予測方法
US20200004928A1 (en) * 2018-06-29 2020-01-02 Roche Sequencing Solutions, Inc. Computing device with improved user interface for interpreting and visualizing data
WO2020021119A1 (fr) * 2018-07-27 2020-01-30 F. Hoffmann-La Roche Ag Procédé de surveillance de l'efficacité d'immunothérapie de patients atteints d'un cancer
TWI745939B (zh) * 2020-04-21 2021-11-11 長庚醫療財團法人林口長庚紀念醫院 偵測周邊血液中ｅｇｆｒ基因突變腫瘤細胞之方法
MX2023007515A (es) * 2020-12-22 2023-09-12 Micronoma Inc Diagnostico y clasificacion del cancer independientes de la taxonomia utilizando acidos nucleicos microbianos y mutaciones somaticas.

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127155A (en) 1986-08-22 2000-10-03 Roche Molecular Systems, Inc. Stabilized thermostable nucleic acid polymerase compositions containing non-ionic polymeric detergents
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
WO1995006137A1 (fr) 1993-08-27 1995-03-02 Australian Red Cross Society Detection de genes
AU2324997A (en) 1996-03-15 1997-10-01 Penn State Research Foundation, The Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
WO2000006770A1 (fr) 1998-07-30 2000-02-10 Solexa Ltd. Biomolecules en rangees et leur utilisation dans une procedure de sequençage
GB0002310D0 (en) 2000-02-01 2000-03-22 Solexa Ltd Polynucleotide sequencing
EP1131153A1 (fr) 1998-11-06 2001-09-12 Solexa Ltd. Procede permettant de reproduire des reseaux moleculaires
WO2000058507A1 (fr) 1999-03-30 2000-10-05 Solexa Ltd. Sequençage de polynucleotide
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
AU7537200A (en) 1999-09-29 2001-04-30 Solexa Ltd. Polynucleotide sequencing
GB0002389D0 (en) 2000-02-02 2000-03-22 Solexa Ltd Molecular arrays
US20030049635A1 (en) 2000-11-08 2003-03-13 City Of Hope Measurement of mutation load using the p53 gene in human cells from paraffin embedded tissues
DE60222628T2 (de) 2001-01-30 2008-07-17 Solexa Ltd., Saffron Walden Herstellung von matrizen aus polynukleotiden
WO2002088388A1 (fr) 2001-04-26 2002-11-07 Ruebben Albert Procede et dispositif de quantification de charges de mutation
WO2003004690A2 (fr) 2001-07-06 2003-01-16 454$m(3) CORPORATION Methode utilisant un filtre poreux pour isoler en parallele des micro-reactions chimiques independantes
GB0119719D0 (en) 2001-08-13 2001-10-03 Solexa Ltd DNA sequence analysis
US6902921B2 (en) 2001-10-30 2005-06-07 454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
WO2004018497A2 (fr) 2002-08-23 2004-03-04 Solexa Limited Nucleotides modifies
PT3438116T (pt) 2002-08-23 2021-03-23 Illumina Cambridge Ltd Nucleótidos identificados
EP1567669B1 (fr) 2002-12-02 2010-03-24 Illumina Cambridge Limited Determination de la methylation de sequences d'acide nucleique
CA2513899C (fr) 2003-01-29 2013-03-26 454 Corporation Procede d'amplification et de sequencage d'acides nucleiques
GB0304371D0 (en) 2003-02-26 2003-04-02 Solexa Ltd DNA Sequence analysis
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
GB0326073D0 (en) 2003-11-07 2003-12-10 Solexa Ltd Improvements in or relating to polynucleotide arrays
EP1701785A1 (fr) 2004-01-07 2006-09-20 Solexa Ltd. Reseaux moleculaires modifies
GB0400584D0 (en) 2004-01-12 2004-02-11 Solexa Ltd Nucleic acid chacterisation
GB0400974D0 (en) 2004-01-16 2004-02-18 Solexa Ltd Multiple inexact matching
GB0402895D0 (en) 2004-02-10 2004-03-17 Solexa Ltd Arrayed polynucleotides
ES2425749T3 (es) 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
EP3042964A1 (fr) 2004-06-04 2016-07-13 Genentech, Inc. Mutations egfr
US7442507B2 (en) 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
EP2505591A1 (fr) 2005-02-11 2012-10-03 Memorial Sloan-Kettering Cancer Center Procédés et compositions pour détecter un mutant d'EGFR résistant aux médicaments
WO2007039705A1 (fr) * 2005-10-05 2007-04-12 Astrazeneca Uk Limited Méthode pour prédire ou surveiller la réponse d'un patient à un médicament de récepteur erbb
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
US8315817B2 (en) 2007-01-26 2012-11-20 Illumina, Inc. Independently removable nucleic acid sequencing system and method
EP2126766A2 (fr) 2007-01-26 2009-12-02 Illumina Inc. Procédé et système de séquençage génétique efficace par données d'image
EP2129791A4 (fr) * 2007-02-26 2010-07-28 Wayne John Cancer Inst Utilite de la mutation d'adn de b-raf dans le diagnostic et le traitement d'un cancer
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
EP2468883A1 (fr) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Biomarqueurs moléculaires pour la prédiction de la réponse aux inhibiteurs de la tyrosine kinase dans le cancer du poumon
US20140227706A1 (en) * 2011-05-16 2014-08-14 Dna Chip Research Inc. Method for assessing progression of clinical state of malignant neoplasm by quantitative detection of DNA in blood
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
ES2662598T3 (es) 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR

Also Published As

Publication number Publication date
CN105229173A (zh) 2016-01-06
US9873913B2 (en) 2018-01-23
JP2019071907A (ja) 2019-05-16
JP7010862B2 (ja) 2022-02-10
JP6480349B2 (ja) 2019-03-06
EP2964781A1 (fr) 2016-01-13
WO2014135669A1 (fr) 2014-09-12
EP2964781B1 (fr) 2018-01-10
ES2662598T3 (es) 2018-04-09
US20140272953A1 (en) 2014-09-18
CA2902099A1 (fr) 2014-09-12
JP2016516395A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
CA2902099C (fr) Analyse de sang destinee a mettre en evidence des mutations de l'egfr
Goldman et al. Are liquid biopsies a surrogate for tissue EGFR testing?
Kodahl et al. Correlation between circulating cell‐free PIK 3 CA tumor DNA levels and treatment response in patients with PIK 3 CA‐mutated metastatic breast cancer
Villaflor et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
Wu et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR
Levine et al. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
Polivka Jr et al. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?
Vandeputte et al. Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
Nong et al. Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients
Wang et al. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung
Demuth et al. A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
Gassa et al. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence
Ohara et al. Clinical significance of perioperative minimal residual disease detected by circulating tumor DNA in patients with lung cancer with a long follow-up data: an exploratory study
Zheng et al. NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China
Marret et al. Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA
Choi et al. Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma
Del Re et al. Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
Sacher et al. Prospective validation of rapid plasma genotyping as a sensitive and specific tool for guiding lung cancer care
US9914975B2 (en) EGFR blood monitoring
Shen et al. Impact of somatic mutations in non-small-cell lung cancer: A retrospective study of a Chinese cohort
Cheng et al. Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: a single-center retrospective study
Pan et al. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
Sankar et al. Molecular biomarkers and liquid biopsies in lung cancer
Chen et al. Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150821

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221